(+)-UH 232 maleate

Pricing Availability Delivery Time Qty
Cat.No. 0775 - (+)-UH 232 maleate | C18H29NO.C4H4O4 | CAS No. 1217473-50-1
Description: D2 autoreceptor antagonist. Also D3 partial agonist
Chemical Name: cis-(+)-5-Methoxy-1-methyl-2-(di-N-propylamino)tetralin maleate

Biological Activity

D2 antagonist (Ki = 72.7 nM in a ligand binding assay; apparent KB = 14.5 nM in a cAMP accumulation assay); displays preferential activity at central dopamine autoreceptors. Stimulates a marked acceleration of dopamine synthesis and turnover. Produces locomotor stimulation. Exhibits little or no activity at central noradrenalin and 5-HT receptors. Also D3 partial agonist.

Technical Data

M. Wt 391.51
Formula C18H29NO.C4H4O4
Storage Store at RT
CAS Number 1217473-50-1
PubChem ID 46830250
Smiles OC(=O)\C=C/C(O)=O.CCCN(CCC)[C@@H]1CCC2=C(C=CC=C2OC)[C@@H]1C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

SolubilitySoluble to 50 mM in water

Preparing Stock Solutions

The following data is based on the product molecular weight 391.51. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.55 mL 12.77 mL 25.54 mL
5 mM 0.51 mL 2.55 mL 5.11 mL
10 mM 0.26 mL 1.28 mL 2.55 mL
50 mM 0.05 mL 0.26 mL 0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis is currently unavailable
on-line. Please contact Customer Service
Safety Datasheet


References are publications that support the products' biological activity.

Griffon et al (1995) The preferential dopamine D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur.J.Pharmacol. 282 R3 PMID: 7498261

Hall and Strange (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br. J. Pharmacol. 121 731 PMID: 9208141

Johansson et al (1985) Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. J.Med.Chem. 28 1049 PMID: 3927002

Svensson et al (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch.Pharmacol. 334 234 PMID: 2880302

If you know of a relevant reference for (+)-UH 232 maleate, please let us know.

View Related Products by Product Action

View all D2 Receptor Antagonists

Keywords: (+)-UH 232 maleate, supplier, D2-like, autoreceptor, antagonists, D3, partial, agonists, Dopamine, Non-Selective, Receptors, dopaminergic, (+)-UH232, maleate, Non-selective, Dopamine, D2, Receptors, D2, Receptors, Tocris Bioscience

Citations for (+)-UH 232 maleate

Citations are publications that use Tocris products.

Currently there are no citations for (+)-UH 232 maleate. Do you know of a great paper that uses (+)-UH 232 maleate from Tocris? If so please let us know.

Reviews for (+)-UH 232 maleate

There are currently no reviews for this product. Be the first to review (+)-UH 232 maleate and earn rewards!

Have you used (+)-UH 232 maleate?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.


Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.


Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.